Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health" or the "Company"), and its dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that Health Canada has approved the Notice of Compliance (NOC) for ARAZLOTM (tazarotene) lotion, 0.045%, for the topical treatment of acne vulgaris (common acne) in patients 10 years of age and older.1
ARAZLO is the first tazarotene acne treatment available in a lotion formulated with PRISMATREXTM technology (a formulation with known hydrating and moisturizers, which may alleviate dryness of skin)1 and has been shown to provide strong efficacy with a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment.
-CISION